Genmab — Maj 2014
-
Men lad os nu først se til ASCO. Der kan vi direkte sidde og sammenligne CR og ORR i SAR+Revlimid og Dara+Revlimid
-
jeg fandt selv svar. SAR tester også 20 mg. så mon ikke vi får data der til ASCO også
-
EMA udsender som regel meeting hoghlights dagen efter mødets sidste dag, så HVIS der er besluttet noget endeligt, er i morgen en mulighed, men highluights omfatter jo ikke alt. Så vidt jeg kan se, så sker det dog tit, at de over flere gange udbeder sig flere oplysninger, så vi får se.
-
-
Empowering progress, knowledge, and partnership. - The European Hematology Association (EHA)
EHA is the leading force in hematology, bringing the community together to share knowledge, collaborate, connect, and grow. Join us now, and enter a world of Borderless Hematology.
The European Hematology Association (EHA) (www.ehaweb.org)
-
Hm. Jeg læste det først som kritisk i forhold til Gazyva, men det hedder i ibrutinib studiet: The design of combined treatment schedules with these kinase inhibitors and anti-CD20 antibodies should therefore consider the multiple negative interactions between these two classes of agents.
-
men gentogen er det ikke fordi de har testet med Ritxuan og Gazyva. De angriber begge ADCC ligesom Kinaserne og vil nok få negative interactions hvorimod Arzerra's CDC killing vil lave fortærskning til kombinationen
-
http://bloodjournal.org/content/123/12/1957?rss=1&variant=short jo det er Ibrutinibs blokering af ADCC, der er problemet
-
I har nok ret, men det er skrevet, så jeg ikke helt forstår det http://files.shareholder.com/downloads/AMDA-KPIBN/3189490857x0x757121/F224E13F-4143-4E97-B339-D03AD9E14257/EHA2014-Ofatumumab-Ibrutinib-Prelinical-DaRoit.pdf
-
Genmab har lagt alle abstracts på hjemmesiden nu http://ir.genmab.com/downloads.cfm
-
The combination of ibrutinib with type II CD20 mAbs does not lead to enhanced direct
cytotoxicity in vitro. In contrast, it inhibits all cell-mediated cytotoxic mechanisms of action of CD20 antibodies and
has minor effects on CDC. Idelalisib has similar, albeit weaker, inhibitory activity on the cell-mediated effector
mechanisms of CD20 mAbs. The design of combined treatment schedules with these kinase inhibitors and anti-
CD20 antibodies should therefore consider the multiple negative interacti -
Key Findings:
• GA101 activates ADCC in cultured human B-cell cancer cells using human
PBMCs or an engineered cell line that expresses FcγRIIIa (Report 1025241,
reviewed below). The ADCC activity is greater in side-by-side comparisons with
rituximab but the magnitude of differences varies with the concentrations of
mAbs used. The addition of nonspecific human IgGs reduces the ADCC
activated by either GA101 or rituximab.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind